Charles Ginsberg1,2, Leila R Zelnick3, Geoffrey A Block4, Glenn M Chertow5, Michel Chonchol6, Andrew Hoofnagle7, Bryan Kestenbaum3, Ian H de Boer3,8. 1. Division of Nephrology-Hypertension, University of California, San Diego, San Diego, CA, USA. 2. Division of Nephrology, Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA. 3. Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, WA, USA. 4. Nephrology, Reata Pharmaceuticals, Inc., Plano, TX, USA. 5. Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA, USA. 6. Division of Renal Diseases and Hypertension, University of Anschutz Medical Center, Aurora, CO, USA. 7. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. 8. VA Puget Sound Health Care System, Seattle, WA, USA.
Abstract
BACKGROUND:Phosphate binders are commonly used in the treatment of patients with hyperphosphatemia. While phosphate binders are used to lower phosphate, the effects of specific phosphate binder types on vitamin D metabolism are unknown. METHODS: We performed a secondary analysis of the Phosphate Normalization Trial in which patients with moderate to advanced chronic kidney disease were randomized to receive either placebo, sevelamer carbonate, lanthanum carbonate or calcium acetate for 9 months. We evaluated changes in serum concentrations of vitamin D metabolites including 24,25-dihydroxyvitamin D3 [24,25(OH)2D3], 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the ratio of 24,25(OH)2D3 to 25-hydroxyvitamin D [the vitamin D metabolite ratio (VMR)] and the ratio of serum 1,25(OH)2D to 25-hydroxyvitamin D. RESULTS: Compared with placebo, randomization to the calcium acetate arm was associated with a 0.6 ng/mL (95% CI 0.2, 1) and 13.5 pg/ng (95% CI 5.5, 21.5) increase in 24,25(OH)2D and VMR, respectively, and a 5.2 pg/mL (95% CI 1.1, 9.4) reduction in 1,25(OH)2D. Randomization to sevelamer carbonate was associated with a 0.5 ng/mL (95% CI -0.9, -0.1) and 11.8 pg/ng (95% CI -20, -3.5) reduction in 24,25(OH)2D3 and VMR, respectively. There was no association of the sevelamer arm with the change in 1,25(OH)2D3, and randomization to lanthanum carbonate was not associated with a change in any of the vitamin D metabolites. CONCLUSION: Administration of different phosphate binders to patients with moderate to severe CKD results in unique changes in vitamin D metabolism.
RCT Entities:
BACKGROUND:Phosphate binders are commonly used in the treatment of patients with hyperphosphatemia. While phosphate binders are used to lower phosphate, the effects of specific phosphate binder types on vitamin D metabolism are unknown. METHODS: We performed a secondary analysis of the Phosphate Normalization Trial in which patients with moderate to advanced chronic kidney disease were randomized to receive either placebo, sevelamer carbonate, lanthanum carbonate or calcium acetate for 9 months. We evaluated changes in serum concentrations of vitamin D metabolites including 24,25-dihydroxyvitamin D3 [24,25(OH)2D3], 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the ratio of 24,25(OH)2D3 to 25-hydroxyvitamin D [the vitamin D metabolite ratio (VMR)] and the ratio of serum 1,25(OH)2D to 25-hydroxyvitamin D. RESULTS: Compared with placebo, randomization to the calcium acetate arm was associated with a 0.6 ng/mL (95% CI 0.2, 1) and 13.5 pg/ng (95% CI 5.5, 21.5) increase in 24,25(OH)2D and VMR, respectively, and a 5.2 pg/mL (95% CI 1.1, 9.4) reduction in 1,25(OH)2D. Randomization to sevelamer carbonate was associated with a 0.5 ng/mL (95% CI -0.9, -0.1) and 11.8 pg/ng (95% CI -20, -3.5) reduction in 24,25(OH)2D3 and VMR, respectively. There was no association of the sevelamer arm with the change in 1,25(OH)2D3, and randomization to lanthanum carbonate was not associated with a change in any of the vitamin D metabolites. CONCLUSION: Administration of different phosphate binders to patients with moderate to severe CKD results in unique changes in vitamin D metabolism.
Authors: Charlotte A Keyzer; G Fenna van Breda; Marc G Vervloet; Maarten A de Jong; Gozewijn D Laverman; Marc H Hemmelder; Wilbert M T Janssen; Hiddo J Lambers Heerspink; Arjan J Kwakernaak; Stephan J L Bakker; Gerjan Navis; Martin H de Borst Journal: J Am Soc Nephrol Date: 2016-11-17 Impact factor: 10.121
Authors: Jessica Kendrick; Emily Andrews; Zhiying You; Kerrie Moreau; Kristen L Nowak; Heather Farmer-Bailey; Douglas R Seals; Michel Chonchol Journal: Clin J Am Soc Nephrol Date: 2017-08-07 Impact factor: 8.237
Authors: Geoffrey A Block; David M Spiegel; James Ehrlich; Ravindra Mehta; Jill Lindbergh; Albert Dreisbach; Paolo Raggi Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: Geert J Behets; Geert Dams; Stephen J Damment; Patrick Martin; Marc E De Broe; Patrick C D'Haese Journal: Am J Physiol Renal Physiol Date: 2013-11-06
Authors: Zona Batacchi; Cassianne Robinson-Cohen; Andrew N Hoofnagle; Tamara Isakova; Bryan Kestenbaum; Kevin J Martin; Myles S Wolf; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2017-08-02 Impact factor: 8.237
Authors: Charles Ginsberg; Andrew N Hoofnagle; Ronit Katz; Jan Hughes-Austin; Lindsay M Miller; Jessica O Becker; Stephen B Kritchevsky; Michael G Shlipak; Mark J Sarnak; Joachim H Ix Journal: J Bone Miner Res Date: 2021-08-29 Impact factor: 6.741